Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

You may be eligible if

• Age greater than or equal to 18.
• Histologically or cytologically confirmed diagnosis of advanced or metastatic renal cell carcinoma for which no effective therapy is available or that is unresponsive to conventional therapy.
• Measurable disease. To be considered measurable, a lesion must be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral CT scan.
• Karnofsky performance status of greater than or equal to 70.
• Be able to have a central venous like access maintained throughout the study.
• Provide written informed consent prior to the initiation of protocol therapy.
• Appropriate organ function.